Marburg Virus Outbreak: Rwanda Reports 20 Cases

Updated Sep 30, 2024 | 09:08 AM IST

SummaryThe latest outbreak in Africa is in Rwanda, it is the Marburg virus which have so far killed 6 people. Read on to know more about it.
Marburg Virus

Credits: Canva

After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.

What Is Marbug Virus?

With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.

Common Signs And Symptoms

The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.

So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).

Call Of Action

Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.

The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.

As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.

This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.

History Of Marburg

As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.

The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.

The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.

In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.

However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.

End of Article

Ebola In DRC Is Still In ‘Expansion Phase’: WHO Doctor Opens About Major Challenges In Containing The Outbreak

Updated Jul 8, 2026 | 01:00 PM IST

SummaryThe recent Ebola outbreak in Congo is nowhere near containment. A WHO official sheds light on ground reality where management of transmission and treatment seems far from easy.
Ebola in DRC Is Still In ‘Expansion Phase’: WHO Doctor Opens About The Challenges In Containing The Outbreak

Credit: AI

The Democratic Republic of Congo is currently in the middle of one of the worst outbreaks in the history of Ebola. On Tuesday, a World Health Organization (WHO) official spoke about the challenges that are making it harder for the authorities to contain the outbreak.

WHO Doctor On Challenges In Containing DRC Ebola Outbreak

Since the outbreak and as of July 4, Congo ⁠has ⁠confirmed 1,561 cases, including 506 deaths, in the worst-ever outbreak of the rare Bundibugyo species of Ebola for which there is no proven treatment or cure yet. Currently, more than 10,000 contacts are being monitored.

Dr Anne Ancia, WHO’s representative to the DRC, said, “It is still in the expansion phase, unfortunately. The outbreak’s true scale has not yet been fully established. We would like to say it is stabilizing, but frankly, we cannot say it yet.”

Speaking from Bunia, the capital of Ituri province, which is at the heart of the outbreak, she added that WHO is strengthening its understanding of the history of every case of infection “so that we can really understand the chain of transmission and isolate every contact case.”

Overwhelmed Treatment Facilities

Pointing to the challenges in containing the outbreak, the WHO representative said that Ebola treatment centres are “at saturation point”. One of the main administrative difficulties that health officials are facing is high occupancy levels, with some around 90%.

She said, “I visited treatment centres in and around Bunia, Beni, Butembo, Katwa, and I met frontline workers responsible for patient care, contact tracing, investigating alerts and sensitising and mobilising communities.”

She also praised the frontline healthcare workers: “I witnessed firsthand the dedication of staff who continue to serve their communities despite enormous challenges."

Dr Ancia added, “Today, we do not have enough ambulances, warning that all the needs in Ituri province cannot be met.

Read more: Uganda Says Ebola Is Contained After Nearly Two Months Of Outbreak; Seeks To Get Travel Restrictions Removed

Population Movement

The WHO official also spoke about the high risk of transmission due to population movement. She said that the workers in the mining town of Mongwbalu are not seeking medical assistance locally, but are travelling to other regions, increasing the risk of transmission in new areas.

Dr Ancia said, “Population movements, persistent insecurity and the fragility of the health system continue to complicate efforts to bring the outbreak under control.”

Misinformation

While updates about new cases of Ebola have not surfaced, misinformation about the disease has been rife in several Congolese communities.

According to the Council on Foreign Relations, there have been reports that some local communities believe that the disease is a hoax or was brought into the country by Western aid workers who wanted to make a profit.

What Makes This Ebola Outbreak Deadlier?

While Ebola is not a new disease, the current outbreak poses a significant threat because it is caused by a rare strain of the virus, Bundibugyo. Unlike previous outbreaks dominated by the Zaire strain of Ebola, the current epidemic, caused by the Bundibugyo virus, is an uncommon species of the Ebola virus family.

The rarity of the strain has created scientific and emergency public health challenges, as there is currently no licensed vaccine to protect against the Bundibugyo Ebola virus.

When Ebola from Zaire strain broke out, vaccination became an important part of outbreak control. Hence, in the current epidemic, public health officials are being forced to rely heavily on rapid diagnosis, infection prevention, surveillance, and existing medical care.

End of Article

GLP-1 Weight-Loss Drug Use Nearly Quadruples In The US Since 2024 As Obesity Rate Continues To Decline

Updated Jul 8, 2026 | 07:15 AM IST

SummaryA recent survey shows the immense popularity of GLP-1 drugs in the United States, as it proved that nearly one in 10 adults now use the medication to lose weight.
GLP-1 Weight-Loss Drug Use Nearly Quadruples In The US Since 2024 As Obesity Rate Continues To Decline

Credit: AI

The popularity of GLP-1 weight-loss medications in the United States has reached its highest level yet. A new survey shows that nearly one in 10 American adults now takes the drugs to lose weight. At the same time, the country's obesity rate shows a steady decline. Experts say the survey does not prove that one trend is directly causing the other.

GLP-1 Weight-Loss Drug Use At An All-Time High In The US

GLP-1 drugs, including medications such as semaglutide and tirzepatide, were originally developed to treat type 2 diabetes but have become increasingly popular for managing obesity after studies showed they could help people lose significant amounts of weight.

According to Gallup's latest National Health and Well-Being Index, 11% of U.S. adults currently use a GLP-1 medication for weight loss. In 2024, this number was just 3%.

The survey also said that 15% of adults have tried a GLP-1 medication at some point, compared to the 6% from two years ago.

The survey also found that 91% of Americans have heard of GLP-1 weight-loss drugs, up from 80% in 2024. The growing visibility of the medication reflects widespread media coverage, celebrity endorsements, and broader acceptance by patients and healthcare providers.

Also read: Serena Williams Lost 34 Pounds With The Help Of A GLP-1 Drug But It’s Not Ozempic

Obesity Rate Has Been Steadily Declining

The Gallup report also found that the adult obesity rate in the US has fallen to 36.4% in 2026, down from a record 39.9% in 2022. The decline follows a similar trend seen last year, when obesity rates also dropped after years of steady increases.

Researchers noted that the decrease in obesity has occurred alongside the rapid rise in GLP-1 use. However, they said that the findings show an association rather than proof that the medications are responsible for the decline in obesity. Other factors, including lifestyle changes, healthcare access, fitness consciousness, and others may also be contributing.

Despite the decline in obesity, the percentage of Americans who have diabetes has remained relatively stable at around 13.5% since 2023, according to Gallup.

Researchers said this is not unexpected because diabetes is a lifelong condition. Even if people lose weight or improve their blood sugar control, they typically continue to be diabetic once diagnosed.

US Medicare To Cover GLP-1 Drugs For Weight Loss

This is another move that will add to the popularity of GLP-1 drugs in the US. From July 1, people in the US will be able to access GLP-1 drugs for weight loss through a new pilot program, offered by the federal health insurance program Medicare. Slated to be operational for 18 months, the program will last till the end of 2027.

Until now, Medicare covered GLP-1 medications like Ozempic only for certain conditions like diabetes, but not for weight loss. The initiative aims to make these high-cost weight-loss medications more accessible to eligible candidates.

Eligible beneficiaries will be able to access the following GLP-1 weight-loss medications:

  • Novo Nordisk's Wegovy injections and tablets
  • Eli Lilly's Foundayo tablets
  • Eli Lilly's Zepbound KwikPen

The medications will be covered only when prescribed for weight management and when beneficiaries meet the program's medical eligibility criteria.

End of Article

Uganda Says Ebola Is Contained After Nearly Two Months Of Outbreak; Seeks To Get Travel Restrictions Removed

Updated Jul 8, 2026 | 07:26 AM IST

SummaryUgandan health authorities recently announced that they have successfully contained the Ebola outbreak as no new cases were reported in the last few days.
Uganda Says Ebola Is Contained After Nearly Two Months Of Outbreak; Seeks To Get Travel Restrictions Removed

Credit: AI

After nearly two months, Uganda has announced that it has successfully contained its latest Ebola outbreak. Authorities say that prompt and aggressive surveillance, rapid treatment, contact tracing, and active cross-border coordination helped stop the spread. The government has now sought the removal of international travel restrictions that were put in place imposed during the outbreak.

Ebola Outbreak In Uganda Contained

The Ugandan Ministry of Health recently said all confirmed Ebola patients have either recovered or completed treatment, while every identified contact has been traced and monitored.

Diana Atwine, Permanent Secretary at the Ministry of Health, said on Sunday in a post on X that the outbreak had been contained. The Xinhua news agency reported that they treated of all imported confirmed cases and cared for those infected. They have also traced and quarantined the contacts.

Atwine also said a large team of medical personnel, two mobile laboratories and logistical support from Uganda were on their way to Congo to support the country's Ebola response.

The Ministry has also implemented preventive measures to curb the spread of the disease from eastern Congo, the epicentre of the ongoing outbreak, Atwine said. It included strengthening screening and preventive measures along the border with the DRC where a much larger Ebola outbreak continues to remain a global concern.

According to the latest figures, the country recorded 20 confirmed Ebola cases, including two deaths. 16 people have recovered from the disease.

The last confirmed infection was reported on June 21. The Health Ministry said that no new cases have been detected and reported since then. Most infections in Uganda were linked to travel from the DRC, while a only a few resulted from local transmission.

Officials argue that the outbreak has been effectively controlled through rapid isolation of patients, extensive contact tracing, quarantine of exposed individuals and supportive medical care.

She added that Uganda had begun urging countries that imposed Ebola-related travel restrictions to lift the measures.

Also read: Uganda On Alert Over Suspected Marburg Virus Outbreak

Ebola Outbreak In The DRC Continues To Remain A Concern

In Congo, the situation is still grim. The capital of Ituri province remains at the heart of the Ebola outbreak. According to latest data, the country has recorded at least 1,561 confirmed cases, including 506 deaths and 254 people recovered. More than 10,000 contacts are being monitored.

Dr. Anne Ancia, WHO’s representative to the DRC said, “True scale has not yet been fully established. We would like to say it is stabilising, but frankly, we cannot say it yet.”

Amid the challenges, a few encouraging developments include the progress made on testing after daily capacity was increased from 30 tests in Kinshasa to more than 2,000 as 10 decentralised laboratories were established in the affected provinces on priority.

Another piece of good news is the start of a clinical trial on July 2, which can help identify and narrow down treatment options for Ebola, as currently there is no approved, proven path of treatment and cure for the Bundibugyo strain.

The trial will examine two promising therapies - a monoclonal antibody, MBP134, and the antiviral remdesivir.

About Bundibugyo Ebola Virus

The Bundibugyo virus was first identified in Uganda in 2007 and has caused only a few outbreaks since then. As infections have been relatively uncommon compared to the Zaire strain, researchers have had limited opportunities to develop vaccines, treatments and diagnostic tests.

Due to this, healthcare workers have been compelled to rely primarily on rapid isolation of patients, intensive supportive care, contact tracing, and strict infection prevention measures to slow transmission.

Currently, Eastern DRC is the hotspot for the Bundibugyo Ebola outbreak, where conflict, population displacement, skepticism, and insecurity have made it difficult for health workers to reach affected locations.

End of Article